Kiniksa Pharmaceuticals International, plc (KNSA) shareholders
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (14.80%) | 6,787,700 | 14.80% | 13G (passive) amendment | Mar 31, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (10.60%) | 4,854,354 | 10.60% | 13G (passive) | Feb 27, 2026 |
| Rubric Capital Management LP Joint filing with David Rosen (7.37%) | 3,328,653 | 7.37% | 13G (passive) amendment | Dec 31, 2025 |
| Felix J. Baker Joint filing with Julian C. Baker (7.00%), Baker Bros. Advisors LP (6.90%) and 1 more | 3,253,341 | 7.00% | 13D (active) amendment | May 21, 2026 |
| BlackRock, Inc. | 2,534,789 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (5.20%) | 2,178,609 | 5.20% | 13G (passive) | Mar 28, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KNSA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 6,971,361 | 4.44% | $445.82M | +147,661 | 0.02% |
| Rubric Capital Management LP | 3,999,800 | 2.55% | $255.79M | +249,800 | 2.35% |
| Baker Bros. Advisors LP | 2,834,643 | 1.80% | $181.28M | +8,397 | 0.91% |
| BlackRock, Inc. | 2,739,615 | 1.74% | $175.20M | +2,252,878 | 0.00% |
| Tang Capital Management LLC | 2,259,889 | 1.44% | $144.52M | – | 6.56% |
| Vanguard Portfolio Management LLC | 1,911,335 | 1.22% | $122.23M | +145,067 | 0.01% |
| Vanguard Capital Management LLC | 1,360,840 | 0.87% | $87.03M | +27,747 | 0.00% |
| Morgan Stanley | 1,011,143 | 0.64% | $64.66M | +13,357 | 0.00% |
| Arrowstreet Capital, Limited Partnership | 957,514 | 0.61% | $61.23M | +64,848 | 0.03% |
| Spruce Street Capital LP | 918,070 | 0.58% | $58.71M | +157,007 | 11.52% |
| Dimensional Fund Advisors LP | 874,786 | 0.56% | $55.94M | +62,864 | 0.01% |
| Invesco Ltd. | 772,806 | 0.49% | $49.42M | +745,150 | 0.00% |
| Driehaus Capital Management LLC | 718,199 | 0.46% | $45.93M | +106,801 | 0.27% |
| State Street Corp | 704,194 | 0.45% | $45.03M | +627,561 | 0.00% |
| Acadian Asset Management LLC | 679,083 | 0.43% | $43.41M | −657,230 | 0.05% |
| Point72 Asset Management, L.P. | 659,493 | 0.42% | $42.17M | +18,535 | 0.05% |
| Rice Hall James & Associates, LLC | 624,928 | 0.40% | $39.96M | +16,512 | 1.95% |
| Pictet Asset Management Holding SA | 608,650 | 0.39% | $38.92M | −14,638 | 0.04% |
| Geode Capital Management, LLC | 604,180 | 0.38% | $38.63M | +559,860 | 0.00% |
| Jupiter Topco LLC | 586,177 | 0.37% | $37.47M | New | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 267 | 47M | 29.9% | 72 / 86 | 81 / 26 | 9M | 7M |
| Q1 2026 | 226 | 45M | 28.9% | 40 / 76 | 84 / 34 | 13M | 8M |
| Q4 2025 | 223 | 43M | 27.3% | 42 / 78 | 70 / 17 | 7M | 4M |
| Q3 2025 | 202 | 41M | 26.1% | 47 / 60 | 69 / 32 | 6M | 5M |
| Q2 2025 | 187 | 40M | 25.4% | 48 / 65 | 61 / 33 | 9M | 9M |
| Q1 2025 | 174 | 40M | 25.4% | 36 / 59 | 56 / 18 | 9M | 7M |
| Q4 2024 | 158 | 39M | 24.8% | 19 / 61 | 58 / 34 | 3M | 4M |
| Q3 2024 | 174 | 40M | 25.3% | 62 / 53 | 42 / 15 | 14M | 5M |
| Q2 2024 | 128 | 35M | 22.4% | 128 / 0 | 0 / 0 | 35M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sanj K. Patel | CHAIRMAN & CEO, Director | 1,602,803 | 1.02% | Nov 6, 2026 |
| John F. Paolini | CHIEF MEDICAL OFFICER | 114,048 | 0.07% | Nov 17, 2026 |
| Michael R. Megna | CHIEF ACCOUNTING OFFICER | 12,697 | 0.01% | Nov 12, 2026 |
| Ross Moat | CHIEF OPERATING OFFICER | 10,294 | 0.01% | Nov 3, 2026 |
| Mark Ragosa | CHIEF FINANCIAL OFFICER | 20,854 | 0.01% | Nov 3, 2026 |
| Dhiraj H. Malkani | CHIEF STRATEGY OFFICER | – | – | Jul 6, 2026 |
| Eben Tessari | CHIEF STRATEGY OFFICER | 23,976 | 0.02% | Apr 8, 2026 |
| Barry D. Quart | Director | 12,745 | 0.01% | Aug 21, 2026 |
| Richard S. Levy | Director | 22,359 | 0.01% | Aug 4, 2026 |
| G. Bradley Cole | Director | 11,672 | 0.01% | Jul 31, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | 123,820 | 0.08% | Jun 2, 2026 |
| Brothers Life Sciences LP Baker | Director | 2,745,259 | 1.75% | Jun 2, 2026 |
| Felix Baker | Director | – | – | Jun 2, 2026 |
| Julian Baker | Director | 158,117 | 0.10% | Jun 2, 2026 |
| Bros. Advisors Lp Baker | Director | – | – | Jun 2, 2026 |
| Kimberly J. Popovits | Director | 15,345 | 0.01% | Jun 2, 2026 |
| Thomas Malley | Director | 87,312 | 0.06% | Jun 2, 2026 |
| Tracey L. McCain | Director | 15,345 | 0.01% | Jun 2, 2026 |
| 667, L.P. | Director | 132,566 | 0.08% | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 13, 2026 | Option exercise | +2,595 | $15.52 | $40.27K | 114,048 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 13, 2026 | Option exercise | +3,144 | $12.97 | $40.78K | 111,453 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 13, 2026 | Option exercise | +3,723 | $11.97 | $44.56K | 108,309 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 13, 2026 | Option exercise | +4,994 | $11.10 | $55.43K | 104,586 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 13, 2026 | Option exercise | +29,670 | $10.36 | $307.38K | 99,592 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Nov 9, 2026 | Sale(10b5-1 plan) | −11,280 | $98.54 | $1.11M | 12,697 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Nov 9, 2026 | Option exercise | +11,280 | $17.76 | $200.33K | 23,977 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 4, 2026 | Sale(10b5-1 plan) | −26,918 | $96.05 | $2.59M | 774,500 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 4, 2026 | Sale(10b5-1 plan) | −29,845 | $95.48 | $2.85M | 801,418 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 4, 2026 | Sale(10b5-1 plan) | −81,742 | $94.20 | $7.70M | 831,263 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 4, 2026 | Sale(10b5-1 plan) | −11,335 | $93.54 | $1.06M | 913,005 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 4, 2026 | Sale(10b5-1 plan) | −1,460 | $92.35 | $134.83K | 924,340 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 4, 2026 | Option exercise | +145,763 | $17.92 | $2.61M | 925,800 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 3, 2026 | Sale(10b5-1 plan) | −4,584 | $94.25 | $432.04K | 780,037 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 3, 2026 | Sale(10b5-1 plan) | −145,708 | $93.53 | $13.63M | 784,621 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 3, 2026 | Sale(10b5-1 plan) | −68,664 | $92.70 | $6.37M | 930,329 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 3, 2026 | Sale(10b5-1 plan) | −1,214 | $90.77 | $110.19K | 998,993 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 3, 2026 | Option exercise | +41,237 | $17.92 | $738.97K | 1,000,207 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 3, 2026 | Option exercise | +89,089 | $8.83 | $786.66K | 958,970 |
| Ross Moat CHIEF OPERATING OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −722 | $94.05 | $67.90K | 10,294 |
| Ross Moat CHIEF OPERATING OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −11,642 | $93.15 | $1.08M | 11,016 |
| Ross Moat CHIEF OPERATING OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −8,932 | $92.05 | $822.19K | 22,658 |
| Ross Moat CHIEF OPERATING OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −6,681 | $91.23 | $609.51K | 31,590 |
| Ross Moat CHIEF OPERATING OFFICER | Nov 2, 2026 | Option exercise | +6,263 | $22.89 | $143.36K | 38,271 |
| Ross Moat CHIEF OPERATING OFFICER | Nov 2, 2026 | Option exercise | +12,302 | $21.77 | $267.81K | 32,008 |
| Ross Moat CHIEF OPERATING OFFICER | Nov 2, 2026 | Option exercise | +9,412 | $18.06 | $169.98K | 19,706 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −220 | $94.01 | $20.68K | 20,854 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −12,034 | $93.13 | $1.12M | 21,074 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −10,502 | $92.03 | $966.50K | 33,108 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −14,027 | $91.40 | $1.28M | 43,610 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Option exercise | +9,636 | $17.76 | $171.14K | 57,637 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Option exercise | +12,123 | $11.97 | $145.11K | 48,001 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Option exercise | +5,388 | $11.10 | $59.81K | 35,878 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Nov 2, 2026 | Option exercise | +9,636 | $10.76 | $103.68K | 30,490 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −704 | $94.09 | $66.24K | 69,922 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −16,810 | $93.42 | $1.57M | 70,626 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −899 | $92.37 | $83.04K | 87,436 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 2, 2026 | Option exercise | +11,958 | $17.92 | $214.29K | 88,335 |
| John F. Paolini CHIEF MEDICAL OFFICER | Nov 2, 2026 | Option exercise | +6,455 | $30.93 | $199.65K | 76,377 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −100 | $93.97 | $9.40K | 869,881 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −26,781 | $93.06 | $2.49M | 869,981 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −24,188 | $91.83 | $2.22M | 896,762 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −38,364 | $91.03 | $3.49M | 920,950 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Nov 2, 2026 | Option exercise | +53,381 | $8.83 | $471.35K | 959,314 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −2,575 | $97.76 | $251.73K | 10,294 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −1,760 | $97.10 | $170.90K | 12,869 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −3,672 | $96.03 | $352.62K | 14,629 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −6,282 | $94.92 | $596.29K | 18,301 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −8,430 | $93.97 | $792.17K | 24,583 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −15,114 | $92.81 | $1.40M | 33,013 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −37,775 | $92.00 | $3.48M | 48,127 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Option exercise | +10,895 | $18.06 | $196.76K | 85,902 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Option exercise | +16,112 | $17.76 | $286.15K | 75,007 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Option exercise | +1,658 | $12.97 | $21.50K | 58,895 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Option exercise | +3,760 | $11.97 | $45.01K | 57,237 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Option exercise | +21,059 | $11.10 | $233.75K | 53,477 |
| Ross Moat CHIEF OPERATING OFFICER | Oct 30, 2026 | Option exercise | +16,111 | $10.76 | $173.35K | 32,418 |
| John F. Paolini CHIEF MEDICAL OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −2,155 | $97.77 | $210.69K | 69,922 |
| John F. Paolini CHIEF MEDICAL OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −1,925 | $97.06 | $186.84K | 72,077 |
| John F. Paolini CHIEF MEDICAL OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −4,000 | $95.97 | $383.88K | 74,002 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kiniksa Pharmaceuticals International's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,617 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark Ragosa Officer | Nov 2, 2026 | 36,783 | $3.39M | Nov 2, 2026 | Employee Stock Option Exercise |
| Sanj K. Patel Officer, Director | Oct 30, 2026 | 553,794 | $51.57M | Oct 30, 2026 | Restricted Stock Lapse - see remarks |
| Ross Moat Officer | Oct 30, 2026 | 103,585 | $9.75M | Oct 30, 2026 | Restricted Stock Lapse |
| Michael R. Megna Officer | Oct 30, 2026 | 47,540 | $4.56M | Oct 30, 2026 | Restricted Stock Lapse - See Remarks |
| John F. Paolini Officer | Oct 30, 2026 | 96,000 | $8.93M | Oct 30, 2026 | Employee Stock Option Exercise - See Remarks |
| Michael R. Megna Officer | Sep 3, 2026 | 4,600 | $369.38K | Sep 3, 2026 | Restricted Stock Lapse |
| G. Bradley Cole Director | Jul 29, 2026 | 3,673 | $299.09K | Jul 29, 2026 | Restricted Stock Lapse |
| Eben Tessari Former Affiliate | Jul 29, 2026 | 67,062 | $5.35M | Jul 29, 2026 | Employee Stock Option Exercise |
| John F. Paolini Officer | May 1, 2026 | 58,424 | $3.14M | May 1, 2026 | Employee Stock Option Exercise |
| Sanj K. Patel Officer, Director | Apr 28, 2026 | 344,591 | $17.78M | Apr 28, 2026 | Employee Stock Option Exercise - See Remarks |
| Ross Moat Officer | Apr 9, 2026 | 1,703 | $79.51K | Apr 9, 2026 | Restricted Stock Lapse |
| Michael R. Megna Officer | Apr 9, 2026 | 6,625 | $309.32K | Apr 9, 2026 | Restricted Stock Lapse |
| Sanj K. Patel Officer, Director | Apr 6, 2026 | 219,591 | $10.98M | Apr 6, 2026 | Employee Stock Option Exercise - See Remarks |
| Barry D. Quart Director | Apr 6, 2026 | 20,000 | $1.00M | Apr 6, 2026 | Employee Stock Option Exercise - see remarks |
| Ross Moat Officer | Apr 6, 2026 | 2,367 | $114.99K | Apr 6, 2026 | Restricted Stock Lapse |
See a number that looks wrong?